Navigation Links
CareFusion Reports First Quarter Fiscal 2012 Results
Date:11/7/2011

nrecurring(in millions)GAAP(4)Items(2)Adjusted(3)Medical SystemsRevenue$

468

$

-

$

468Operating Income $

68

$

22

$

90Procedural SolutionsRevenue$

343

$

-

$

343Operating Income $

11

$

17

$

28____________1Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring charges.  2Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.  Certain nonrecurring costs previously reported were applicable to the International Surgical Products (ISP) business and therefore were reclassified to be reflected as part of that business.3Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.4Previously reported GAAP amounts have been adjusted to reflect the impact of the divestiture of the ISP business, and re-segmentation of the Company's businesses into two new reportable segments.  The ISP business was divested in April 2011, and has been classified as discontinued operations. CAREFUSION CORPORATIONSEGMENT AND SELECT BUSINESS LINE REVENUES(UNAUDITED)Quarter Ended September 30,(in millions) 20112010(1)Percent
ChangeMedical SystemsDispensing Technologies

$

237

$

205

16

%Infusion Systems206192

7Respiratory Technologies6065

(8)Other66

-Total Medical Systems

$

509

$

468

9Procedural SolutionsInfection Prevention

$

138

$

135

2

%Medical Specialties7878

-Specialty Disposables6670

(6)Other5360

(12)Total Procedural Solutions

$

335

$

343

(2)Total CareFusion$

844

$

811

4

%____________1Previously rep
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
4. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Neurocrine Biosciences Reports Third Quarter 2011 Results
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... SAN DIEGO , July 28, 2015  Kerastem ... conditional approval from the U.S. FDA Center For Biologics ... Gene Therapies to conduct a clinical trial investigating the ... treatment of female and early male pattern baldness (androgenic ... the STYLE trial, follows initial clinical work in ...
(Date:7/28/2015)... CITY , July 28, 2015 /PRNewswire/ - Aeterna ... today announced that it has granted to German ... funding the development and commercialization of biotechnology (collectively, ... live recombinant oral allogenic tumor vaccine technology (the ... for prostate cancer which is ready to enter ...
(Date:7/27/2015)... 27, 2015  Amgen (NASDAQ: AMGN ) today ... results on Thursday, July 30, 2015, after the close ... followed by a conference call with the investment community ... Amgen will be Robert A. Bradway , chairman ... senior management team. Live audio of the ...
(Date:7/27/2015)... ... , ... Production of high tenacity filament yarn of viscose rayon (excluding sewing ... instance, it surpassed the EUR 106 million mark (in value terms) in 2013, while ... major producer, while Italy is a key consumer. , The high tenacity filament ...
Breaking Biology Technology:Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2High Tenacity Filament Yarn of Viscose Rayon Consumption to Grow Swiftly in the EU, Forecasts BAC Reports in New Study Available at MarketPublishers.com 2
... , , , , For purification of endotoxin-free ultrapure , ... Features and benefits , , Less ... DNA , Greater than 90% recovery of plasmid DNA , ... , , , ...
... , , , A crucial step ... To improve the critical steps in the target-labeling process, , ... for use with Affymetrix GeneChip expression arrays. The GeneChip ... of an ongoing collaboration between , QIAGEN and ...
... , , , , , , ... specific and sensitive multiplex PCR without the need for time-consuming , optimization ... , , ... ready-to-use master mix , High specificity ...
Cached Biology Technology:EndoFree Plasmid Kits 2EndoFree Plasmid Kits 3EndoFree Plasmid Kits 4GeneChip Sample Cleanup Module for cleanup of cDNA and in vitro , transcribed cRNA 2QIAGEN Multiplex PCR Kit 2QIAGEN Multiplex PCR Kit 3
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... than 70 researchers across the globe has uncovered nine ... lead to learning disabilities. The international team studied almost ... disabilities - the largest screen of this type ever ... approximately 1𔃀% of X chromosome genes, when knocked-out, have ...
... for places that can soak up carbon dioxide from the ... gas include the oceans and the enormous trees of tropical ... research now suggests they can store more carbon than previously ... and present-day datasets, Jeanine Rhemtulla of McGill University and David ...
... Five-hundred years ago, Ponce de Leon combed the swamps of ... the 2009 ASBMB Annual Meeting in New Orleans (held in ... exciting talks centering on the new molecular "fountain of youth," ... of longevity may still be a long time away, the ...
Cached Biology News:The genetic X-factor 2The genetic X-factor 3Study reveals potential to amass more carbon in eastern North American forests 2Study reveals potential to amass more carbon in eastern North American forests 3ASBMB Annual Meeting to feature talks on the biochemistry of aging 2ASBMB Annual Meeting to feature talks on the biochemistry of aging 3
...
Agarose, Biotechnology grade, 500g...
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
...
Biology Products: